GlassScriptPhysician profile
Sarah Vanover
NPI 1629557087
$1,730.38
in general payments reported to CMS, 2019-2025
21 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $354 · 2023: $409 · 2024: $721 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,376.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $438.06 | 2022-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $271.35 | 2023-2024 | Qelbree, Qelbree |
| Seqirus USA INC | $161.77 | 2022-2024 | Flucelvax Quadrivalent, Flucelvax |
| Neos Therapeutics, LP | $150.90 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Noven Therapeutics, LLC | $87.61 | 2023-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $84.85 | 2022 | |
| Ironshore Pharmaceuticals INC. | $70.37 | 2022-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $54.63 | 2022-2024 | Vaxneuvance, Gardasil, Proquad |
| Pfizer INC. | $50.88 | 2024-2025 | |
| Cranial Technologies, INC | $50.13 | 2022-2025 | Doc Band |
| Tris Pharma INC | $46.60 | 2022-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $45.31 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $45.22 | 2023 | Bexsero |
| Sanofi Pasteur INC. | $38.12 | 2023-2024 | |
| Sobi, INC | $31.47 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.28 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $19.90 | 2025 | Exparel |
| Biomarin Pharmaceutical INC. | $19.20 | 2024 | Voxzogo 1.2mg |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.09 | 2023 | |
| Neurelis, INC. | $13.40 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.24 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Vanover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.